HK1205114A1 - Asymmetric syntheses for spiro oxindole compounds useful as therapeutic agents - Google Patents

Asymmetric syntheses for spiro oxindole compounds useful as therapeutic agents

Info

Publication number
HK1205114A1
HK1205114A1 HK15105599.7A HK15105599A HK1205114A1 HK 1205114 A1 HK1205114 A1 HK 1205114A1 HK 15105599 A HK15105599 A HK 15105599A HK 1205114 A1 HK1205114 A1 HK 1205114A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic agents
compounds useful
asymmetric syntheses
oxindole compounds
spiro oxindole
Prior art date
Application number
HK15105599.7A
Other languages
English (en)
Chinese (zh)
Inventor
Shaoyi Sun
Jianmin Fu
Sultan Chowdhury
William Hemeon Ivan
Edward Grimwood Michael
Suhayl Mansour Tarek
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of HK1205114A1 publication Critical patent/HK1205114A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
HK15105599.7A 2012-04-12 2015-06-12 Asymmetric syntheses for spiro oxindole compounds useful as therapeutic agents HK1205114A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623336P 2012-04-12 2012-04-12
PCT/US2013/030219 WO2013154712A1 (en) 2012-04-12 2013-03-11 Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents

Publications (1)

Publication Number Publication Date
HK1205114A1 true HK1205114A1 (en) 2015-12-11

Family

ID=47902379

Family Applications (3)

Application Number Title Priority Date Filing Date
HK15105599.7A HK1205114A1 (en) 2012-04-12 2015-06-12 Asymmetric syntheses for spiro oxindole compounds useful as therapeutic agents
HK15105598.8A HK1205113A1 (en) 2012-04-12 2015-06-12 Asymmetric syntheses for spiro oxindole compounds useful as therapeutic agents
HK16114577A HK1226389A1 (zh) 2012-04-12 2015-06-12 用作治療劑的螺-羥吲哚化合物的不對稱合成

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK15105598.8A HK1205113A1 (en) 2012-04-12 2015-06-12 Asymmetric syntheses for spiro oxindole compounds useful as therapeutic agents
HK16114577A HK1226389A1 (zh) 2012-04-12 2015-06-12 用作治療劑的螺-羥吲哚化合物的不對稱合成

Country Status (14)

Country Link
US (2) US9487535B2 (xx)
EP (1) EP2838902B1 (xx)
JP (1) JP6195609B2 (xx)
KR (1) KR20150002794A (xx)
CN (2) CN104350057A (xx)
AU (1) AU2013246485A1 (xx)
CA (1) CA2869547A1 (xx)
EA (1) EA201491854A1 (xx)
ES (1) ES2714314T3 (xx)
HK (3) HK1205114A1 (xx)
IL (1) IL235006A0 (xx)
MX (1) MX2014012266A (xx)
WO (1) WO2013154712A1 (xx)
ZA (1) ZA201407334B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
EP2733145A1 (en) 2009-10-14 2014-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
PE20121699A1 (es) 2010-02-26 2012-12-22 Xenon Pharmaceuticals Inc Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
CN104350057A (zh) 2012-04-12 2015-02-11 泽农医药公司 用作治疗剂的螺-羟吲哚化合物的不对称合成
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2017180248A1 (en) * 2016-04-15 2017-10-19 William Marsh Rice University Enantioenriched viridicatumtoxin b analogs
WO2017214442A1 (en) 2016-06-08 2017-12-14 President And Fellows Of Harvard College Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
CN109311905A (zh) * 2016-06-16 2019-02-05 泽农医药公司 螺-吲哚酮化合物的固态形式
CN108395438A (zh) * 2018-04-03 2018-08-14 陕西科技大学 一类具有抗菌活性的靛红母核螺环化合物及其合成方法
US11434244B2 (en) 2018-05-29 2022-09-06 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
EP4161656A4 (en) 2020-06-05 2024-06-19 Kinnate Biopharma Inc. INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723459A (en) 1971-04-23 1973-03-27 Mc Neil Labor Inc 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives
JPS6130554A (ja) 1984-07-23 1986-02-12 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
DE3608088C2 (de) 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
CA1322197C (en) 1987-07-17 1993-09-14 Bernd Buchmann 9-halogen-(z) prostaglandin derivatives, process for their production and their use as pharmaceutical agents
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
PT1008588E (pt) 1997-02-10 2003-09-30 Ono Pharmaceutical Co Derivados da 11,15-o-diaklquil-prostaglandina e processo de producao dos mesmos e farmaco que os contem como ingrediente activo
US6262293B1 (en) 1997-12-25 2001-07-17 Ono Pharmaceutical Co., Ltd. ω-Cycloalkly-prostaglandin e2 derivatives
JP4087938B2 (ja) 1998-02-04 2008-05-21 高砂香料工業株式会社 ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
WO2005035498A1 (ja) 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. 含窒素二環性化合物の摂食調節剤としての用途
MXPA06012660A (es) 2004-05-05 2007-03-23 Unibioscreen Sa Derivados de naftalimida para el tratamiento de cancer.
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
EP1924264B9 (en) 2005-09-01 2014-02-19 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2007081895A2 (en) * 2006-01-09 2007-07-19 Merck & Co., Inc. Preparation of substituted 2-hydroxygibba-1(10a), 2, 4, 4b-tetraen-6-ones
CL2007002950A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Uso de compuestos derivados de espiro-oxindol en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer
WO2008046087A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro compounds and their uses as therapeutic agents
US20110294842A9 (en) 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
CA2666136A1 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
US8263606B2 (en) * 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
US8295257B2 (en) 2009-03-13 2012-10-23 Telcordia Technologies, Inc. Scalable disruptive-resistant communication method
WO2010132352A2 (en) * 2009-05-11 2010-11-18 Xenon Pharmaceuticals Inc. Spiro compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (en) 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
EP2733145A1 (en) 2009-10-14 2014-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
PE20121699A1 (es) 2010-02-26 2012-12-22 Xenon Pharmaceuticals Inc Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
CN104350057A (zh) 2012-04-12 2015-02-11 泽农医药公司 用作治疗剂的螺-羟吲哚化合物的不对称合成

Also Published As

Publication number Publication date
IL235006A0 (en) 2014-12-31
US20170066777A1 (en) 2017-03-09
EA201491854A1 (ru) 2015-03-31
US9487535B2 (en) 2016-11-08
CN105753877A (zh) 2016-07-13
ZA201407334B (en) 2017-05-31
JP6195609B2 (ja) 2017-09-13
KR20150002794A (ko) 2015-01-07
HK1226389A1 (zh) 2017-09-29
EP2838902B1 (en) 2018-12-05
HK1205113A1 (en) 2015-12-11
MX2014012266A (es) 2014-12-05
EP2838902A1 (en) 2015-02-25
US20130274483A1 (en) 2013-10-17
JP2015516389A (ja) 2015-06-11
ES2714314T3 (es) 2019-05-28
AU2013246485A1 (en) 2014-10-16
WO2013154712A1 (en) 2013-10-17
CA2869547A1 (en) 2013-10-17
CN104350057A (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
IL286152A (en) Modified imidazopyridinyl-aminopyridine compounds
HK1205113A1 (en) Asymmetric syntheses for spiro oxindole compounds useful as therapeutic agents
IL237212A (en) Amino derivatives of benzoimidazole carboxylic acid as receptor modulators for apj
EP2673286A4 (en) THERAPEUTIC COMPOUNDS
HK1210472A1 (en) Spirocyclic derivatives as antiparasitic agents
PL2776416T3 (pl) Związki farmaceutyczne
IL228945A0 (en) Modified bicyclylmethylamine derivatives as sphingosine-1-phosphate receptor modulators
HK1201534A1 (en) Pharmaceutical compounds
EP2717694A4 (en) NEW COMPOUNDS
GB201119799D0 (en) Pharmaceutical compounds
GB201205164D0 (en) Pharmaceutical compounds
IL233002A0 (en) New compounds for neural modulation
GB201118876D0 (en) Pharmaceutical compounds
GB201113163D0 (en) Pharmaceutical compounds
HK1216619A1 (zh) 藥物化合物
CO6870043A2 (es) Procedimiento de preparación de compuestos de pirazol n-sustituidos
EP2768814A4 (en) NOVEL NON-STEROID COMPOUNDS AS MODULATORS OF AN ANDROGEN RECEPTOR
IL236873A0 (en) therapeutic compounds
GB201118875D0 (en) Pharmaceutical compounds
GB201118874D0 (en) Pharmaceutical compounds
GB201117359D0 (en) Pharmaceutical compounds
GB201105026D0 (en) Pharmaceutical compounds
GB201211308D0 (en) Compounds for use
GB201219236D0 (en) Pharmaceutical compounds
GB201214121D0 (en) Pharmaceutical compounds